Stansberry Asset Management’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-40,474
| Closed | -$119K | – | 129 |
|
|
2024
Q4 | $119K | Sell |
40,474
-43,463
| -52% | -$127K | 0.02% | 123 |
|
|
2024
Q3 | $218K | Sell |
83,937
-4,473
| -5% | -$11.6K | 0.03% | 124 |
|
|
2024
Q2 | $262K | Sell |
88,410
-4,878
| -5% | -$14.4K | 0.03% | 122 |
|
|
2024
Q1 | $423K | Sell |
93,288
-6,698
| -7% | -$30.3K | 0.06% | 110 |
|
|
2023
Q4 | $571K | Sell |
99,986
-12,481
| -11% | -$71.3K | 0.09% | 100 |
|
|
2023
Q3 | $517K | Buy |
112,467
+9,792
| +10% | +$45K | 0.09% | 100 |
|
|
2023
Q2 | $663K | Buy |
102,675
+1,138
| +1% | +$7.35K | 0.12% | 87 |
|
|
2023
Q1 | $766K | Buy |
101,537
+1,361
| +1% | +$10.3K | 0.15% | 88 |
|
|
2022
Q4 | $1.01M | Buy |
100,176
+2,026
| +2% | +$20.5K | 0.21% | 80 |
|
|
2022
Q3 | $971K | Sell |
98,150
-2,365
| -2% | -$23.4K | 0.21% | 72 |
|
|
2022
Q2 | $1.07M | Sell |
100,515
-2,448
| -2% | -$26.1K | 0.23% | 68 |
|
|
2022
Q1 | $1M | Buy |
102,963
+7,048
| +7% | +$68.7K | 0.16% | 78 |
|
|
2021
Q4 | $1.37M | Buy |
95,915
+56,941
| +146% | +$814K | 0.22% | 58 |
|
|
2021
Q3 | $781K | Buy |
+38,974
| New | +$781K | 0.16% | 51 |
|